Asset
AB-101
Artiva Biotherapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04673617 | phase1_2 | completed | 2021-03-29 | 2025-10-06 | Artiva Biotherapeutics, Inc. | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |
| NCT06265220 | phase1 | active_not_recruiting | 2024-04-03 | 2027-08-01 | Artiva Biotherapeutics, Inc. | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus |
FDA applications (0)
This company has no applications containing this asset.